Stay updated with breaking news from Responsive Auto Regulatory Element. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Initiation of REVEAL pediatric trial in the U.S.broadens the clinical evaluation of TSHA-102 to female patients 5-8 years old with stage three Ret...
Available clinical data from the two adult patients dosed with TSHA-102 in the first cohort (low dose) to be discussed during upcoming quarterly e...
Fast Track Designation is designed to accelerate the development and expedite the review of therapies with potential to address unmet medical needs for a serious or life-threatening condition ...
Operator: Thank you for standing by. This is the conference operator. Welcome to the Taysha Gene Therapies First Quarter 2023 Earnings Conference Call.
Taysha Gene Therapies faces potential delisting of its shares—the latest in a series of setbacks that include scrapping a $75-million manufacturing facility in Durham, NC.